Literature DB >> 9590723

Intraoperative radiation therapy for a patient with bulky disease of mesenteric non-Hodgkin's lymphoma.

H Yamaue1, H Tanimura, H Terasawa, Y Nakatani, T Tsunoda, M Tani, M Iwahashi.   

Abstract

A long survival is rarely observed in patients demonstrating recurrent malignant lymphoma with bulky disease because of the appearance of chemoresistant tumor cells after extensive chemotherapy, and moreover the presence of bulky disease has also been consistently associated with a poorer response rate and a shortened survival, due to the fact that tumor size is the most significant factor for the treatment of non-Hodgkin's lymphoma. We herein describe a case of a 53-year-old woman presenting with the chief complaint of abdominal fullness, who underwent intraoperative radiation therapy (IORT) for recurrent bulky non-Hodgkin's lymphoma in the mesenterium. The patient has had no evidence of tumor recurrence, based on the findings of regular abdominal computed tomographic scans, 60 months after initial chemotherapy and 28 months after IORT.

Entities:  

Mesh:

Year:  1998        PMID: 9590723     DOI: 10.1007/s005950050167

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  20 in total

1.  Clinical and immunological evaluation of intraoperative radiation therapy for patients with unresectable pancreatic cancer.

Authors:  H Yamaue; H Tanimura; Y Aoki; T Tsunoda; M Iwahashi; M Tani; M Tamai; K Noguchi; H Kashiwagi; M Sasaki
Journal:  J Surg Oncol       Date:  1992-01       Impact factor: 3.454

2.  Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin.

Authors:  P Comella; G Abate; G Di Finizio; A Daponte; D Zarrilli
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Management of advanced, resistant Hodgkin's disease and non-Hodgkin's lymphoma: a phase II study.

Authors:  S F Williams; J E Ultmann; E Gaynor; S Watson
Journal:  Cancer Treat Rep       Date:  1986-08

4.  Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay.

Authors:  H Yamaue; H Tanimura; M Nakamori; K Noguchi; M Iwahashi; M Tani; T Hotta; K Murakami; K Ishimoto
Journal:  Dis Colon Rectum       Date:  1996-04       Impact factor: 4.585

5.  Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy.

Authors:  W S Velasquez; L M Fuller; S Jagannath; S L Tucker; L B North; F B Hagemeister; P McLaughlin; F Swan; J R Redman; M A Rodriguez
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113

6.  ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

Authors:  W S Velasquez; P McLaughlin; S Tucker; F B Hagemeister; F Swan; M A Rodriguez; J Romaguera; E Rubenstein; F Cabanillas
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

7.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Malignant lymphoma of the rectum treated preoperatively with hyperthermia and radiation.

Authors:  R Shimono; M Mori; A Kido; Y Adachi; K Sugimachi
Journal:  Eur J Surg Oncol       Date:  1995-02       Impact factor: 4.424

9.  Prognostic factors in stage I and II high and intermediate grade non-Hodgkin's lymphoma.

Authors:  J F Mackintosh; R A Cowan; M Jones; M Harris; D P Deakin; D Crowther
Journal:  Eur J Cancer Clin Oncol       Date:  1988-10

10.  Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay.

Authors:  H Yamaue; H Tanimura; K Noguchi; T Hotta; M Tani; T Tsunoda; M Iwahashi; M Tamai; S Iwakura
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.